On May 29, Akeso Bio rose 3.99% in regular trading, trading at 112.8 HKD/share, with trading volume of HKD 106 million. The rally was driven by the official opening of the ASCO Annual Meeting, where the company's core product ivonescimab's HARMONi-6 study has been selected for a plenary session oral presentation — the only China-originated innovative drug study featured in this year's ASCO plenary session.

The presentation will disclose overall survival data from a head-to-head comparison against tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer. This marks the first time a First-in-Class bispecific antibody from China has been featured in an ASCO plenary session, generating significant market anticipation for the key survival endpoints.

Notably, the stock had been under sustained pressure following disappointing interim results from the global Phase III HARMONi-3 study, with shares declining over 25% from prior highs. Today's rebound suggests the imminent plenary data release is serving as a near-term re-rating catalyst amid broader biotech sector weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)